A recent study carried out by some experts in the University of Nottingham, Ningbo University and Shanxi Agricultural University in China has come up with a dynamic conclusion.
Their study has found that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various types of tumours.
The findings of the study were published in the 'Journal for ImmunoTherapy Cancer.Through the new study it was revealed that a parasite which is found commonly across the globe had the potentials to sensitise cold tumours- tumours that are not likely to trigger a strong immune response by the body-to immune checkpoint blockade therapy.
This treatment has the ability to stop the tumour progression and promote a longer life to the patient.Scientist leading the study believe that the finding could have broader therapeutic implications for many types of cancer.
This treatment has the ability to stop the tumour progression and promote longer life for the patient.
The research team managed to tame the parasite Toxoplasma gondii-a single-celled opportunistic protozoan capable of infecting a broad range of warm-blooded animals and has been reported in nearly one-third of the world's human population.
The research shows that if the mutant parasite is directly injected into the solid tumour, it induces inflammatory responses in the injected tumour and even those tumours located in distant locations in the mouse body.
This treatment approach has made tumours more responsive to treatment with immune checkpoint inhibitors. A senior researcher associated with this study said that the use of a mutant variant of Toxoplasma gondii in the treatment of certain tumours in mice models show that it significantly reduces the size of the tumour and helps in providing longevity.